"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial looking at chemotherapy for prostate cancer that has stopped responding to treatment (CL56)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at 2 chemotherapy drugs called lomustine and chlorambucil for men with prostate cancer that was no longer responding to hormone therapy. Doctors call this hormone refractory prostate cancer.
The aim of this trial was to see how well the combination of lomustine and chlorambucil works for men with prostate cancer when hormone treatment has stopped working. And to find out more about side effects.
Summary of results
The researchers found that two thirds of men in this trial responded to the combination of lomustine and chlorambucil.
This small trial recruited 37 men. Everybody who took part had lomustine and chlorambucil. The men had an average of 2 treatment cycles each.
The doctors analysed the results in 2005. They looked at PSA blood test results following treatment to find out how well treatment worked. They found
- In 1 man the PSA level returned to a normal level for at least 4 weeks – researchers called this '
- In 2 men, the PSA level halved and did not rise again for at least 4 weeks – researchers called this ‘
- In 17 men the PSA level stayed the same for at least 8 weeks – researchers called this ‘
- In 12 men the PSA continued to rise, or a CT scan showed the cancer had continued to grow
- They didn’t have the results for 5 men
The main side effects were mild and included tiredness and constipation. A very small number of men had a drop in blood counts.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr J Shamash
Barts Health NHS Trust